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Th  ree recently published articles in Critical Care con-
cerning the usefulness of procalcitonin (PCT) in critically 
ill patients elicited this cautionary comment of the 
present article’s title [1-3]. PCT has been introduced as a 
test with high sensitivity and speciﬁ   city for bacterial 
infection in patients in the emergency department. Th  e 
test’s negative predictive value is thought to be suﬃ   cient 
to withhold antibiotics in cases of low PCT [4,5]. PCT 
has also been evaluated as a diagnostic tool in critically ill 
patients. Th  is would be of help because there is no 
immediately available test that proves or disproves a 
bacterial infec  tion. Especially, the number of true and 
false negative patients cannot be estimated. We therefore 
cannot deter  mine the test characteristics of PCT in these 
patients. We can determine with more certainty the true 
positive patients and measure their PCT level.
Between March 2007 and April 2008 we registered all 
patients presenting to the emergency department, the 
ICU or wards of internal medicine meeting the criteria of 
the Surviving Sepsis Campaign guidelines for severe 
sepsis or septic shock. In these patients we measured the 
PCT level with the PCT-Q test (Brahms, Henningsdorf, 
Germany) at presentation, and microbiological analysis 
(blood cultures, sputum cultures and urine cultures) was 
performed. Microbiological proven sepsis was deﬁ  ned by 
a positive blood culture result (except cultures with 
Staphylococcus epidermidis) or by positive culture results 
other than blood in the presence of two or more systemic 
inﬂ  ammatory response syndrome criteria.
In the above-mentioned period we included 132 
patients. Patient characteristics are displayed in Table 1. 
A total of 63 (47%) patients had proven sepsis or septic 
shock. Blood cultures were taken in 127 patients, of 
which 40 patients (30.3%) were positive. In 101 patients 
with blood cultures taken, the PCT level was measured at 
presentation (Table 2). Th  irty-two patients had PCT 
levels <0.5 ng/ml, of which eight patients (25%) had 
positive blood cultures.
Based on these results we conclude that PCT levels can 
be misleading. It is unsafe to withhold antibiotics based 
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Table 1. Characteristics of the 132 patients included in the 
analysis
Number of patients (n) 132
Age (years)a  65.3 ± 1.3 
  (22.7 to 96.0)
Male (%)  64.4
Survival (%)  74.2
PCT analysis at presentation performed (n) 110
Number of patients with PCT <0.5 ng/ml (n (%))  34 (25.8)
Number of patients with PCT 0.5 to 2.0 ng/ml (n (%))  21 (21.2)
Number of patients with PCT 2.0 to 10.0 ng/ml (n (%))  27 (20.5)
Number of patients with PCT >10.0 ng/ml (n (%))  28 (21.2)
Number of blood cultures conducted (% positive fi  ndings)  127 (30.3)
Number of sputum cultures conducted (% positive fi  ndings)  24 (33.3)
Number of urine cultures conducted (% positive fi  ndings)  79 (25.3)
Number of pus cultures conducted (% positive fi  ndings)  26 (65.4)
PCT, procalcitonin. aData presented as mean ± standard error of the mean 
(range).
Table 2. Procalcitonin results in negative and positive 
blood cultures
                                       Blood cultures (n)
Procalcitonin at 
presentation Negative  Positive  Total  (n)
<0.5 ng/ml  24  8  32
0.5 to 2.0 ng/ml  16  5  21
2.0 to 10.0 ng/ml  13  10  23
>10.0 ng/ml  12  13  25
Total 65  36  101
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© 2011 BioMed Central Ltdon a test with unknown test characteristics, such as PCT, 
in patients presenting with criteria meeting the Surviving 
Sepsis Campaign guidelines for severe sepsis or septic 
shock. Fortunately, the Surviving Sepsis Campaign 
bundle is clear on this point and these patients received 
appropriate antibiotics in accordance with this guideline.
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